Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP.

By Yannan Zhao, B. Trewyn, Igor I. Slowing, V. S. Lin. Journal of the American Chemical Society, 2009

709 citations recorded by the source corpus.

Subfields: Molecular Biology, Pharmaceutical Science, Surgery

View Paper: https://www.semanticscholar.org/paper/322b93e73fc1f292d6e481eb46d800b163416c6a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmaceutical Science

1. Xueting Lin
2. B. Homayun
3. Hyo-Jick Choi

Citations in the corpus

• Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals (2019, background): “The co-delivery of insulin and cyclic adenosine monophosphate (cAMP) was proposed to enhance the secretion of further insulin by activating the Ca2+ channels in beta cells of the pancreas [195].”
• High drug-loading nanomedicines: progress, current status, and prospects (2017, neutral): “Although silica is considered generally recognized as safe and has secured FDA approval for Phase I human clinical trials, 49 in vivo studies have described dose-dependent toxicity, 50 such as inflammatory response, 51 liver injury, 52 neurotoxicity, and pregnancy complications.”